Advertisement
Australia markets close in 4 hours 53 minutes

  • ALL ORDS

    7,848.50
    -89.00 (-1.12%)
     

  • ASX 200

    7,589.10
    -93.90 (-1.22%)
     

  • AUD/USD

    0.6528
    +0.0005 (+0.08%)
     

  • OIL

    83.94
    +0.37 (+0.44%)
     

  • GOLD

    2,341.30
    -1.20 (-0.05%)
     

  • Bitcoin AUD

    98,201.98
    -542.05 (-0.55%)
     

  • CMC Crypto 200

    1,388.04
    +5.47 (+0.40%)
     

  • AUD/EUR

    0.6084
    +0.0010 (+0.17%)
     

  • AUD/NZD

    1.0945
    -0.0013 (-0.12%)
     

  • NZX 50

    11,879.14
    -67.29 (-0.56%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,284.54
    0.00 (0.00%)
     

  • NIKKEI 225

    37,644.00
    +15.52 (+0.04%)
     

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

Kura Oncology, Inc.
·2-min read
Kura Oncology, Inc.
Kura Oncology, Inc.

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel titled “Bullseye - Targeted Oncology – In with the New” at 10:20 a.m. ET / 7:20 a.m. PT on Tuesday, August 9, 2022.

A live audio webcast of the panel will be available in the Investors section of Kura’s website at www.kuraoncology.com, with a replay available shortly after the live event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable FTI, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company is also preparing to initiate a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in treatment-naïve locally advanced/metastatic EGFR mutated NSCLC. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company’s next-generation FTI, through IND-enabling studies. For additional information, please visit Kura’s website at www.kuraoncology.com.

ADVERTISEMENT

Contacts

Company:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com